ESH MDS 2024 | Chronological age no longer dictates eligibility for allogeneic transplantation in patients with MDS
Didier Blaise, MD, PhD, Institut Paoli-Calmettes, Marseille, France, summarizes advances in allogeneic transplantation for older patients with myelodysplastic syndromes (MDS). Dr Blaise highlights that although transplantation eligibility was previously based on patient age, this is no longer a determining factor and further explains that frailty is a more accurate indicator of transplantation eligibility and positive clinical outcome. This interview took place at the European School of Hematology 9th Translational Research Conference on Myelodysplastic Syndromes (ESH MDS) in Budapest, Hungary.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
